For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation ...

A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...

This article was reviewed by Lynn Marie Morski, MD, JD Key Takeaways: Peptides are compounds made of amino acids linked by ...

For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation in the digestive tract and the absence of a dedicated intestinal transport ...

Researchers from Kumamoto University have developed a new peptide-based technology that enables insulin—normally injected—to be taken orally while still powerfully lowering blood sugar. Their ...

Dr Anne Peters discusses updates in the ADA 2026 Standards of Care in Diabetes, focusing on the use of technology.

- ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC37 injection, a next-generation, once-monthly, subcutaneously administered GLP-1R/GIPR/GCGR[1] triple peptide agonist, ...

This comparative effectiveness study found that initiation of sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in individuals with type ...

LMNT reports that GLP-1 medications for obesity and diabetes may lead to electrolyte imbalances, highlighting hydration ...

In the sophisticated world of endocrinology and molecular biology, few compounds have sparked as much curiosity as CJC-1295 DAC. As a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), this ...